Stephen Kilmer - IBio, Common Investor Officer
| IBIO Stock | USD 4.63 0.07 1.54% |
Insider
Stephen Kilmer is Investor Officer of iBio, Common Stock
| Phone | 979 446 0027 |
| Web | https://ibioinc.com |
IBio, Common Management Efficiency
The company has return on total asset (ROA) of (0.2973) % which means that it has lost $0.2973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8415) %, meaning that it created substantial loss on money invested by shareholders. IBio, Common's management efficiency ratios could be used to measure how well IBio, Common manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Cini | Sonnet Biotherapeutics Holdings | 72 | |
| MD FAAP | BioCryst Pharmaceuticals | 57 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 67 | |
| Elliott Berger | BioCryst Pharmaceuticals | N/A | |
| Cyndi Tolman | ADMA Biologics | N/A | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Kaitlin Kestenberg | ADMA Biologics | 37 | |
| William MBBS | BioCryst Pharmaceuticals | 70 | |
| Michael Goldstein | ADMA Biologics | N/A | |
| Cezar MBA | Vaxart Inc | 51 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 70 | |
| Brant Biehn | Vaxart Inc | N/A | |
| James MD | Vaxart Inc | 59 | |
| CPA CPA | ADMA Biologics | 52 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Dr Stapleton | Vaxart Inc | 53 | |
| CPA MBA | Vaxart Inc | 72 | |
| Fuad Ahmad | Vaxart Inc | 54 | |
| MD FAAAAI | Palisade Bio | N/A | |
| PharmD BCOP | ADMA Biologics | N/A | |
| Michael Least | ADMA Biologics | N/A | |
Management Performance
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.3 |
iBio, Common Stock Leadership Team
Elected by the shareholders, the IBio, Common's board of directors comprises two types of representatives: IBio, Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IBio,. The board's role is to monitor IBio, Common's management team and ensure that shareholders' interests are well served. IBio, Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IBio, Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Middlebrook, Chief Officer | ||
| Stephen Kilmer, Investor Officer | ||
| Marc JD, General Counsel | ||
| Melissa Berquist, VP Health | ||
| Robert Lutz, Chief Officer | ||
| Robert Kay, Executive Chairman and CEO | ||
| Dr DVM, Chief Officer | ||
| Mike Jenkins, VP Operations | ||
| Thomas III, Pres CEO | ||
| Randy Maddux, Strategic Advisor | ||
| Kristi Sarno, Senior Development | ||
| Felipe Duran, Chief Officer | ||
| Nick DeLong, VP Devel |
IBio, Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IBio, Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (19.48) % | ||||
| Current Valuation | 40.33 M | ||||
| Shares Outstanding | 9.14 M | ||||
| Shares Owned By Insiders | 0.14 % | ||||
| Shares Owned By Institutions | 31.92 % | ||||
| Number Of Shares Shorted | 307.8 K | ||||
| Price To Earning | (2.18) X | ||||
| Price To Book | 3.12 X |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.